Expanding the development business to four pillars by adding the medical field
First written in FY2016. 11 of 32 entries say "Advanced", first in FY2018-Q1. Latest entry: 2026-11-10.
No other company in this theme has enough history to compare yet.
- FY2026WorsenedAnnual report
「Sales of our core product, powder dialysate dissolvers, remained sluggish, resulting in revenue of ¥747 million for this field, down 1.6% from the previous fiscal year.」
While sales of core products had been described as firm in the previous fiscal year, medical equipment revenue declined in the current fiscal year due to sluggish sales. - FY2026-H1MitigatedAnnual report
「Sales of our core product, powder dialysate dissolvers, remained firm, resulting in revenue of ¥363 million, up 0.3% year on year.」
For medical equipment, where a decline in revenue from core products had been reported in the previous period, sales remained firm and increased 0.3% year on year. - FY2025Decline in revenue from core products alongside the rollout of new productsAnnual report
「For medical equipment, we are progressively redesigning our core powder dialysate dissolvers in response to market demand. In addition, our endotoxin meters using bioluminescence technology have been well received for their high sensitivity and short measurement times. To expand the endotoxin meter lineup, we launched sales of products offering even shorter measurement times and simpler operation.」
While revenue from powder dialysate dissolvers fell 14.8% from the previous fiscal year, we proceeded with model changes, expanded the endotoxin meter lineup and began selling new products. - FY2025-H1AdvancedAnnual report
「Sales of new OEM models remained strong, resulting in revenue of ¥362 million for this field, up 9.4% year on year.」
For medical equipment, sales of new OEM models remained strong, driving a 9.4% year-on-year increase in revenue. - FY2024RestatedAnnual report
「In this field, OEM inventory adjustments for existing models were made ahead of new-model sales, resulting in revenue of ¥891 million, down 13.2% from the previous fiscal year.」
For medical equipment, the full-year results also cited lower revenue due to OEM inventory adjustments for existing models ahead of new-model sales. - FY2024-Q3Sales decline due to OEM inventory adjustments ahead of a new modelAnnual report
「In the medical equipment business, sales amounted to ¥603 million, down 14.5% year on year, due to OEM inventory adjustments for existing models ahead of the sale of a new model.」
For medical equipment, OEM inventory adjustments for existing models ahead of new-model sales were newly cited as a factor behind the decline in revenue. Revenue fell 14.5% year on year, but the decline narrowed from 25.3% in the previous quarter. - FY2024-Q2WorsenedAnnual report
「Demand related to the recovery from the COVID-19 pandemic had run its course, and sales in this business amounted to ¥331 million, down 25.3% year on year.」
Medical equipment sales declined 25.3% year on year against the backdrop of the end of demand related to the recovery from the COVID-19 pandemic, widening the decline from 15.4% in the previous quarter. - FY2024-Q1WorsenedAnnual report
「In the medical equipment business, whose key product is the powder-type dialysate dissolving machine, demand related to the recovery from the COVID-19 pandemic had run its course, and sales in this business amounted to ¥135 million, down 15.4% year on year.」
In the medical equipment business, sales declined 15.4% year on year as demand related to the recovery from the COVID-19 pandemic had run its course. - FY2023AdvancedAnnual report
「Orders remained high in this business, and sales amounted to ¥1,026 million, up 7.3% from the previous fiscal year.」
In the medical equipment business, orders remained high and sales increased 7.3% from the previous fiscal year. - FY2023-Q3RestatedAnnual report
「Orders in the medical equipment business remained high, but sales were limited to ¥704 million, up 2.0% year on year, due to the impact of extended lead times for procuring materials.」
In the medical equipment business, order levels remained high, while the recognition of sales continued to be constrained by extended lead times for procuring materials. - FY2023-Q2High order levels and sales constrained by extended lead timesAnnual report
「Orders in this business remained high, but sales were limited to ¥443 million, up 1.6% year on year, due to the impact of extended lead times for procuring materials.」
In the medical equipment business, order levels remained high, while sales growth was constrained by extended lead times for procuring materials. - FY2023-Q1WorsenedAnnual report
「Orders remained strong in both the scientific analytical instruments business, comprising laboratory analytical instruments and portable analyzers, and the medical equipment business, whose key product is the powder-type dialysate dissolving machine. However, due to the impact of extended delivery times caused by difficulties in procuring materials, sales in these businesses declined 7.0% and 22.4%, respectively, year on year.」
Orders for scientific analytical instruments and medical equipment remained strong, while sales declined 7.0% and 22.4%, respectively, year on year due to extended delivery times caused by difficulties in procuring materials. - FY2022AdvancedAnnual report
「Sales of laboratory analytical instruments and portable analyzers increased slightly, while the medical equipment business recorded higher sales as orders for the powder-type dialysate dissolving machine, its key product, remained steady. As a result, sales in this business increased 4.2% from the previous fiscal year.」
In the medical equipment business, orders for the key product remained steady, and sales in the scientific analytical instruments business increased 4.2% from the previous fiscal year. - FY2022-Q3RestatedAnnual report
「In the medical equipment business, sales of the key product increased, while orders grew substantially further. As a result, sales in this business increased 6.8% year on year.」
In the medical equipment business, increased sales of the key product and substantial growth in orders continued, and sales in the scientific analytical instruments business increased 6.8% year on year. - FY2022-Q2MitigatedAnnual report
「Recent sales of laboratory analytical instruments and portable analyzers declined, but orders increased steadily. Meanwhile, sales of the powder-type dialysate dissolving machine, a key medical equipment product, increased, and orders grew substantially further. As a result, sales in this business increased 3.2% year on year.」
In the medical equipment business, the trend shifted from declining recent sales through the previous fiscal year to increased sales of the key product, while orders also grew substantially further. Total sales in the scientific analytical instruments business increased 3.2% year on year. - FY2022-Q1Orders increased while sales declinedAnnual report
「Although orders for the powder-type dialysate dissolving machine, a key medical equipment product, have been increasing, recent sales declined.」
The divergence between orders and sales for the powder-type dialysate dissolving machine continued to be reported, with orders trending upward while recent sales declined. - FY2021-Q3Demand continued to decline, but the revenue decline narrowedAnnual report
「Sales of the powder-type dialysate dissolving machine, a key medical equipment product, also declined as hospitals’ demand for new installations and replacements decreased. As a result, sales in this business decreased 8.1% year on year.」
The decline in hospitals’ demand for new installations and replacements and the resulting lower sales of the key product continued. Meanwhile, the decline in total sales in the scientific analytical instruments business narrowed from 9.1% year on year to 8.1%. - FY2021-Q2WorsenedAnnual report
「Sales of the powder-type dialysate dissolving machine, a key medical equipment product, also declined as hospitals’ demand for new installations and replacements decreased. As a result, sales in this business decreased 9.1% year on year.」
Although sales of the key product had been described as performing steadily in the previous quarter, sales in the scientific analytical instruments business declined 9.1% year on year due to lower hospital demand for new installations and replacements. - FY2021-Q1MitigatedAnnual report
「Meanwhile, sales of the powder-type dialysate dissolving machine, a key medical equipment product, remained firm.」
For the medical equipment business, which had been reported through the previous fiscal year as experiencing lower sales due to delivery schedule adjustments by certain OEM customers, sales of the key product were reported to be performing steadily. - FY2020-Q3WorsenedAnnual report
「Sales of the powder-type dialysate dissolving machine, a key medical equipment product, were below the same period of the previous year due to delivery schedule adjustments by certain OEM customers.」
In the medical equipment business, sales remained below the same period of the previous year, with delivery schedule adjustments by certain OEM customers newly identified as a factor. - FY2020-Q2Orders increased while sales declinedAnnual report
「Sales of the powder-type dialysate dissolving machine, a key medical equipment product, were below the same period of the previous year, but orders have been increasing, and full-year sales are expected to be at approximately the same level as in the previous fiscal year.」
In the medical equipment business, sales were below the same period of the previous year, while the upward trend in orders and the forecast for full-year sales to remain at approximately the previous fiscal year’s level were presented together. - FY2020-Q1AdvancedAnnual report
「The powder-type dialysate dissolving machine, a key medical equipment product, continued to be affected by a wait-and-see stance toward consumption tax trends, but orders have been increasing.」
The medical equipment business showed tangible progress in the form of an upward trend in orders, rather than sales performance. - FY2019-Q3AdvancedAnnual report
「In the scientific analytical instruments business, the powder-type dialysate dissolving machine, a key medical equipment product, has been adopted as a standard product by major dialysis system manufacturers, and increased production for new contract customers at the new production building, which began operating in the second half of the previous fiscal year, contributed to sales. Sales of laboratory analytical instruments also remained strong, and sales increased 9.4% year on year.」
In the medical equipment business, standard adoption by major manufacturers and increased production for new contract customers at the new production building continued to contribute, and sales in the scientific analytical instruments business increased 9.4% year on year. - FY2019-Q2AdvancedAnnual report
「The powder-type dialysate dissolving machine, a key medical equipment product, has been adopted as a standard product by major dialysis system manufacturers, and increased production for new contract customers at the new production building, which began operating in the second half of the previous fiscal year, contributed to sales. Sales of laboratory analytical instruments also remained strong, and sales increased 8.6% year on year.」
In addition to standard adoption by major manufacturers, increased production for new contract customers at the new production building contributed to an 8.6% year-on-year increase in scientific analytical instrument sales. - FY2019-Q1AdvancedAnnual report
「In the scientific analytical instruments business, the powder-type dialysate dissolving machine, a key medical equipment product, has been adopted as a standard product by major dialysis system manufacturers. The new production building is also operating at full capacity, and increased production for new contract customers that began in the second half of the previous fiscal year contributed to a 14.5% year-on-year increase in sales.」
The medical equipment business showed tangible progress, including standard adoption by major manufacturers, full-scale operation of the new production building, the contribution from increased production for new contract customers and a 14.5% year-on-year increase in sales. - FY2018AdvancedAnnual report
「In October 2017, a new production building for medical equipment began operations. Sales increased 10.8% year on year as production of the powder-type dialysate dissolving machine, a key product, was expanded.」
The new medical equipment production building began operations in October 2017, resulting in increased production of the key product and a 10.8% year-on-year increase in sales. - FY2018-Q3AdvancedAnnual report
「Sales increased 14.9% year on year as a new production building dedicated to medical equipment began operations and full-scale mass production of the powder-type dialysate dissolving machine, a key product, commenced.」
A new production building dedicated to medical equipment began operations, and full-scale mass production of the key product commenced. Sales of medical equipment also increased 14.9% year on year. - FY2018-Q2AdvancedAnnual report
「Sales increased 11.0% year on year as the distinctive design quality of the powder-type dialysate dissolving machine, a key medical equipment product, received high praise, leading to increased orders from major medical equipment manufacturers.」
Sales of medical equipment increased 11.0% year on year, driven by increased orders from major medical equipment manufacturers. - FY2018-Q1AdvancedAnnual report
「In the scientific analytical instruments business, sales increased 14.6% year on year, reflecting the expansion of production for major medical equipment manufacturers after the distinctive design quality of the powder-type dialysate dissolving machine, a key medical equipment product, received high praise.」
The medical equipment business showed tangible progress, including increased production for major medical equipment manufacturers and a 14.6% year-on-year increase in sales. - FY2016First statedAnnual report
「Development strategy: We aim to expand the business from the three development pillars to four by adding the medical field.」
The Company presented a policy of expanding the business to four pillars by adding the medical field to the former three development pillars.